Platelet-rich plasma impairs osteoclast generation from human precursors of peripheral blood

Elisabetta Cenni, Sofia Avnet, Caterina Fotia, Manuela Salerno, Nicola Baldini

Research output: Contribution to journalArticle

Abstract

Platelet-rich plasma is used to accelerate bone repair for the release of osteogenic growth factors from activated platelets. To date, the effects on osteoclasts have been only scarcely investigated, even though these cells are crucial for bone remodeling. The aim of this research was the evaluation of the effects of thrombin-activated platelets (PRP) on osteoclastogenesis from human blood precursors. We evaluated both the ability to influence osteoclast differentiation induced by the receptor activator of nuclear factor-kappaB ligand (RANKL), and the ability to induce osteoclast differentiation without RANKL. In both assays, the incubation with PRP supernatant at 10% did not significantly affect the formation of tartrate-resistant acid phosphatase (TRACP)-positive multinucleated cells that were able to form the F-actin ring. However, when PRP at 25 and 50% was added to the medium without RANKL, the generation of TRACP-positive multinucleated cells was inhibited. PRP, even at 10%, reduced the osteoclast-mediated bone collagen degradation, suggesting inhibition of osteoclast activation. Similarly, after incubation with PRP supernatant, calcitonin receptor mRNA was lower than the untreated samples. In conclusion, PRP at 10% interfered with the complete differentiation process of human osteoclast precursors. At higher concentration it impaired osteoclast formation also at an early stage of differentiation.

Original languageEnglish
Pages (from-to)792-797
Number of pages6
JournalJournal of Orthopaedic Research
Volume28
Issue number6
DOIs
Publication statusPublished - Jun 2010

Fingerprint

Platelet-Rich Plasma
Osteoclasts
RANK Ligand
Blood Platelets
Calcitonin Receptors
Bone and Bones
Bone Remodeling
Osteogenesis
Thrombin
Actins
Intercellular Signaling Peptides and Proteins
Collagen
Messenger RNA

Keywords

  • Growth factor
  • Osteoclast
  • Platelet-rich plasma

ASJC Scopus subject areas

  • Orthopedics and Sports Medicine

Cite this

Platelet-rich plasma impairs osteoclast generation from human precursors of peripheral blood. / Cenni, Elisabetta; Avnet, Sofia; Fotia, Caterina; Salerno, Manuela; Baldini, Nicola.

In: Journal of Orthopaedic Research, Vol. 28, No. 6, 06.2010, p. 792-797.

Research output: Contribution to journalArticle

@article{02ade538b03746c4b8c8a807f70e1e78,
title = "Platelet-rich plasma impairs osteoclast generation from human precursors of peripheral blood",
abstract = "Platelet-rich plasma is used to accelerate bone repair for the release of osteogenic growth factors from activated platelets. To date, the effects on osteoclasts have been only scarcely investigated, even though these cells are crucial for bone remodeling. The aim of this research was the evaluation of the effects of thrombin-activated platelets (PRP) on osteoclastogenesis from human blood precursors. We evaluated both the ability to influence osteoclast differentiation induced by the receptor activator of nuclear factor-kappaB ligand (RANKL), and the ability to induce osteoclast differentiation without RANKL. In both assays, the incubation with PRP supernatant at 10{\%} did not significantly affect the formation of tartrate-resistant acid phosphatase (TRACP)-positive multinucleated cells that were able to form the F-actin ring. However, when PRP at 25 and 50{\%} was added to the medium without RANKL, the generation of TRACP-positive multinucleated cells was inhibited. PRP, even at 10{\%}, reduced the osteoclast-mediated bone collagen degradation, suggesting inhibition of osteoclast activation. Similarly, after incubation with PRP supernatant, calcitonin receptor mRNA was lower than the untreated samples. In conclusion, PRP at 10{\%} interfered with the complete differentiation process of human osteoclast precursors. At higher concentration it impaired osteoclast formation also at an early stage of differentiation.",
keywords = "Growth factor, Osteoclast, Platelet-rich plasma",
author = "Elisabetta Cenni and Sofia Avnet and Caterina Fotia and Manuela Salerno and Nicola Baldini",
year = "2010",
month = "6",
doi = "10.1002/jor.21073",
language = "English",
volume = "28",
pages = "792--797",
journal = "Journal of Orthopaedic Research",
issn = "0736-0266",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Platelet-rich plasma impairs osteoclast generation from human precursors of peripheral blood

AU - Cenni, Elisabetta

AU - Avnet, Sofia

AU - Fotia, Caterina

AU - Salerno, Manuela

AU - Baldini, Nicola

PY - 2010/6

Y1 - 2010/6

N2 - Platelet-rich plasma is used to accelerate bone repair for the release of osteogenic growth factors from activated platelets. To date, the effects on osteoclasts have been only scarcely investigated, even though these cells are crucial for bone remodeling. The aim of this research was the evaluation of the effects of thrombin-activated platelets (PRP) on osteoclastogenesis from human blood precursors. We evaluated both the ability to influence osteoclast differentiation induced by the receptor activator of nuclear factor-kappaB ligand (RANKL), and the ability to induce osteoclast differentiation without RANKL. In both assays, the incubation with PRP supernatant at 10% did not significantly affect the formation of tartrate-resistant acid phosphatase (TRACP)-positive multinucleated cells that were able to form the F-actin ring. However, when PRP at 25 and 50% was added to the medium without RANKL, the generation of TRACP-positive multinucleated cells was inhibited. PRP, even at 10%, reduced the osteoclast-mediated bone collagen degradation, suggesting inhibition of osteoclast activation. Similarly, after incubation with PRP supernatant, calcitonin receptor mRNA was lower than the untreated samples. In conclusion, PRP at 10% interfered with the complete differentiation process of human osteoclast precursors. At higher concentration it impaired osteoclast formation also at an early stage of differentiation.

AB - Platelet-rich plasma is used to accelerate bone repair for the release of osteogenic growth factors from activated platelets. To date, the effects on osteoclasts have been only scarcely investigated, even though these cells are crucial for bone remodeling. The aim of this research was the evaluation of the effects of thrombin-activated platelets (PRP) on osteoclastogenesis from human blood precursors. We evaluated both the ability to influence osteoclast differentiation induced by the receptor activator of nuclear factor-kappaB ligand (RANKL), and the ability to induce osteoclast differentiation without RANKL. In both assays, the incubation with PRP supernatant at 10% did not significantly affect the formation of tartrate-resistant acid phosphatase (TRACP)-positive multinucleated cells that were able to form the F-actin ring. However, when PRP at 25 and 50% was added to the medium without RANKL, the generation of TRACP-positive multinucleated cells was inhibited. PRP, even at 10%, reduced the osteoclast-mediated bone collagen degradation, suggesting inhibition of osteoclast activation. Similarly, after incubation with PRP supernatant, calcitonin receptor mRNA was lower than the untreated samples. In conclusion, PRP at 10% interfered with the complete differentiation process of human osteoclast precursors. At higher concentration it impaired osteoclast formation also at an early stage of differentiation.

KW - Growth factor

KW - Osteoclast

KW - Platelet-rich plasma

UR - http://www.scopus.com/inward/record.url?scp=77951445405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951445405&partnerID=8YFLogxK

U2 - 10.1002/jor.21073

DO - 10.1002/jor.21073

M3 - Article

C2 - 20058277

AN - SCOPUS:77951445405

VL - 28

SP - 792

EP - 797

JO - Journal of Orthopaedic Research

JF - Journal of Orthopaedic Research

SN - 0736-0266

IS - 6

ER -